Source comparison
Comparison Table: MOTS-c Timeline vs Other Metabolic Peptides
MOTS-c 2–4 hours (AMPK activation) 2–4 weeks (insulin sensitivity, glucose uptake) 8–12 weeks (mitochondrial biogenesis, substrate oxidation shift) Mitochondrial-derived peptide that activates AMPK and upregulates PGC-1α, promoting mitochondrial biogenesis and
This comparison does not assign a generated winner or score.
- MOTS-c
- 2–4 hours (AMPK activation)
- 2–4 weeks (insulin sensitivity, glucose uptake)
- 8–12 weeks (mitochondrial biogenesis, substrate oxidation shift)
- Mitochondrial-derived peptide that activates AMPK and upregulates PGC-1α, promoting mitochondrial biogenesis and fatty acid oxidation
- Slowest onset but targets root metabolic dysfunction. Mitochondrial capacity and insulin sensitivity. Rather than masking symptoms
- CJC1295 Ipamorelin
- 15–30 minutes (GH pulse)
- 4–6 weeks (lean mass accrual, lipolysis)
- 12–16 weeks (body composition remodeling)
- Growth hormone secretagogue that increases endogenous GH pulses, indirectly enhancing lipolysis and protein synthesis
- Faster subjective energy boost but slower fat oxidation improvement than MOTS-c; primarily anabolic rather than metabolic
- AOD9604
- 1–2 hours (lipolytic signaling)
- 1–2 weeks (fat mobilization)
- 6–8 weeks (regional fat reduction)
- Fragment of human growth hormone (hGH 176-191) that stimulates lipolysis without affecting insulin or IGF-1 levels
- Fastest onset for fat loss but does not improve insulin sensitivity or mitochondrial function. Purely lipolytic, not metabolic
- Tesamorelin
- 30–60 minutes (GH release)
- 4–8 weeks (visceral fat reduction)
- 12–20 weeks (sustained fat loss, lipid profile improvement)
- GHRH analog that selectively reduces visceral adipose tissue through sustained GH elevation
- Comparable timeline to MOTS-c for visceral fat but works through GH axis rather than direct mitochondrial signaling
- MOTS-c is not the fastest-acting metabolic peptide, but it addresses metabolic dysfunction at the mitochondrial level. A depth other peptides don't reach. AOD9604 mobilizes fat faster, but it doesn't correct the insulin resistance or mitochondrial inefficiency that allowed the fat to accumulate. MOTS-c takes longer to show results because it's remodeling cellular energy metabolism, not just stimulating lipolysis.